Matthew Whitaker Wilson

Matthew Whitaker Wilson

Auto-generated profile, based on publicly available information

Matthew Whitaker Wilson

Hamilton Eye Institute. Department of Ophthalmology. University of Tennessee. Memphis, TN, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AWAnderson H. Webb
Anderson H. Webb
BGBradley T. Gao
Bradley T. Gao
ZGZachary K. Goldsmith
Zachary K. Goldsmith
AIAndrew S. Irvine
Andrew S. Irvine
NSNabil Saleh
Nabil Saleh
VMVanessa Morales-Tirado
Vanessa Morales-Tirado
Retinoblastoma (Rb) is the most common primary intraocular tumor in children. Local treatment of the intraocular disease is usually effective if diagnosed early; however advanced Rb can metastasize through routes that involve invasion of the choroid, sclera and optic nerve or more broadly via the ocular vasculature. Metastatic Rb patients have very high mortality rates. While current therapy for Rb is directed toward blocking tumor cell division and tumor growth, there are no specific treatments targeted to block Rb metastasis. Two such targets are matrix metalloproteinases-2 and -9 (MMP-2, −9), which degrade extracellular matrix as a prerequisite for cellular invasion and have been shown to be involved in other types of cancer metastasis. Cancer Clinical Trials with an anti-MMP-9 therapeutic antibody were recently initiated, prompting us to investigate the role of MMP-2, −9 in Rb metastasis. We compare MMP-2, −9 activity in two well-studied Rb cell lines: Y79, which exhibits high metastatic potential and Weri-1, which has low metastatic potential. The effects of inhibitors of MMP-2 (ARP100) and MMP-9 (AG-L-66085) on migration, angiogenesis, and production of immunomodulatory cytokines were determined in both cell lines using qPCR, and ELISA. Cellular migration and potential for invasion were evaluated by the classic wound-healing assay and a Boyden Chamber assay. Our results showed that both inhibitors had differential effects on the two cell lines, significantly reducing migration in the metastatic Y79 cell line and greatly affecting the viability of Weri-1 cells. The MMP-9 inhibitor (MMP9I) AG-L-66085, diminished the Y79 angiogenic response. In Weri-1 cells, VEGF was significantly reduced and cell viability was decreased by both MMP-2 and MMP-9 inhibitors. Furthermore, inhibition of MMP-2 significantly reduced secretion of TGF-β1 in both Rb models. Collectively, our data indicates MMP-2 and MMP-9 drive metastatic pathways, including migration, viability and secretion of angiogenic factors in Rb cells. These two subtypes of matrix metalloproteinases represent new potential candidates for targeted anti-metastatic therapy for Rb.

1 August 2009 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
XSXavier Sastre
Xavier Sastre
GCGuillermo L Chantada
Guillermo L Chantada
DFDoz François
Doz François
MWMatthew W Wilson
Matthew W Wilson
MDMaria T G De Davila
Maria T G De Davila
IGInternational Retinoblastoma Staging Working Group
International Retinoblastoma Staging Working Group
Retinoblastoma is the most common intraocular malignant childhood tumor in need of prospective clinical trials to address important unanswered questions about biology, treatment, and prognostic factors. Currently, there is controversy about the definitions for choroidal invasion and an inconsistency in the handling of eyes with retinoblastoma. The International Retinoblastoma Staging Working Group (IRSWG) composed of 58 participants from 24 countries on 4 continents had a series of Internet meetings to discuss the staging and tissue handling guidelines to reach consensus for adequate processing, establishing definitions of histopathologic risk factors, and reporting of enucleated eyes with retinoblastoma to serve as the basis for clinical trials and studies to validate the proposed criteria. The meetings were facilitated by the International Outreach Program of the St. Jude Children's Research Hospital through Cure4Kids. The retinoblastoma guidelines from the Children's Oncology Group, the French Society for Pediatric Cancers, the Association of Directors of Anatomic and Surgical Pathology, and some published data were the basis for this consensus document. Discussions of the feasibility, practicality, and efficacy of the guidelines and criteria resulted in this report. The consensus definitions reached included definition of massive choroidal invasion stated as a maximum diameter of invasive tumor focus of 3 mm or more that may reach the scleral tissue. Focal choroidal invasion is defined as a tumor focus of less than 3 mm and not reaching the sclera. Optic nerve invasion is classified as prelaminar, laminar, retrolaminar, or tumor at surgical margin, and the measurement of the depth of invasion should also be recorded. These guidelines also address handling of the enucleated eye with retinoblastoma in an efficient, practical, and feasible manner for a meaningful diagnosis. The consensus criteria reached by the IRSWG should be validated through prospective clinical trials and studies.

7 August 2010 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
MWMatthew W Wilson
Matthew W Wilson
IQIbrahim Qaddoumi
Ibrahim Qaddoumi
CBCatherine Billups
Catherine Billups
BHBarrett G Haik
Barrett G Haik
CRCarlos Rodriguez-Galindo
Carlos Rodriguez-Galindo
Aims To correlate the clinical and histopathological findings of eyes primarily enucleated for advanced intraocular retinoblastoma. Methods In a retrospective study, the authors identified patients primarily enucleated for advanced intraocular retinoblastoma. The authors retrieved patient demographics, clinical findings, subsequent treatments and outcomes, and reviewed the histopathology of each eye for invasion of the anterior chamber, iris, ciliary body, choroid, sclera and optic nerve, and extraocular extension. The authors used the Fisher exact, exact Jonkheere–Terpstra, exact Wilcoxon rank sum and Kruskal–Wallis statistical tests (p<0.05) to study associations between clinical and histopathological findings. Results The authors identified 67 eyes of 67 patients (33 males) primarily enucleated for retinoblastoma between March 1997 and January 2008. Corneal diameter, intraocular pressure and Reese–Ellsworth Classification had no significant association with invasive disease. The International Classification, however, was associated with optic nerve (p=0.026), choroid (p<0.001), ciliary body (p=0.002), iris (p=0.002), anterior chamber (p=0.025) and scleral (p<0.001) invasion. Eyes classified as International Classification Group E were more likely to have invasion of these sites and have more severe optic-nerve invasion. Conclusions Corneal diameter, intraocular pressure and Reese–Ellsworth Classification do not correlate with histopathological evidence of invasive retinoblastoma. Eyes classified as International Classification Group E are more likely to have elevated intraocular pressure, invasion of the anterior chamber, uveal tract, optic nerve and sclera. The findings warrant primary enucleation with meticulous histopathological examination of such eyes prior to any adjuvant therapy.

1 July 2013 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
BTBrian C. Tse
Brian C. Tse
JSJena Steinle
Jena Steinle
DJDianna Johnson
Dianna Johnson
BHBarrett G. Haik
Barrett G. Haik
MWMatthew W. Wilson
Matthew W. Wilson
Superselective intraophthalmic artery chemotherapy (SSIOAC) has come to the forefront in the treatment of retinoblastoma, without the benefit of preclinical modeling.1 Real-time ophthalmoscopic observations of SSIOAC in a nonhuman primate (NHP) model were described elsewhere.2 Multiple acute ocular vascular sequelae were documented, including ophthalmic artery (OA) thrombosis, narrowing of the OA and retinal arteries, pulsatile optic nerve and retinal edema, retinal artery sheathing and precipitates, and choroid blanching and hypoperfusion.

1 May 2007 in Ophthalmology
Verified
Journal Article
Closed access
MWMatthew W. Wilson
Matthew W. Wilson
MHMary Ellen Hoehn
Mary Ellen Hoehn
BHBarrett G. Haik
Barrett G. Haik
MRMartha Rieman
Martha Rieman
URUlrike Reiss
Ulrike Reiss

1 April 2006 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
MWMatthew W. Wilson
Matthew W. Wilson
CFCharles H. Fraga
Charles H. Fraga
CFChristine E. Fuller
Christine E. Fuller
CRCarlos Rodriguez-Galindo
Carlos Rodriguez-Galindo
JMJohn Mancini
John Mancini
CSClinton F. Stewart
Clinton F. Stewart
Purpose. To compare the expression of multidrug-resistant proteins in retinoblastoma tumors among eyes treated with primary enucleation. methods. A group of 18 patients with unilateral retinoblastoma with advanced intraocular disease was selected for the study. All patients had undergone primary enucleation. A histologic specimen from each patient was retrieved from the pathology archives and a tissue gene microarray was constructed (0.6 × 3–4 mm). Standard immunohistochemical techniques were used to study the tissue microarrays for the expression of the ATP-binding cassette (ABC) transporters: breast cancer resistance protein (BCRP; ABCG2), multidrug-resistant protein 1/P-glycoprotein (MDR1/Pgp; ABCB1), multidrug-resistant–associated protein 1 (MRP1; ABCC1), MRP2 (ABCC2), and MRP4 (ABCC4). results. Of the 18 specimens retrieved, 16 had adequate tissue for study. MRP1 was expressed in 8 (50%) of 16 tumors, and MRP2 was expressed in 5 (31%) of 16 tumors. MDR1/Pgp was found in 2 (12%) of 16 retinoblastomas. MRP4 and BCRP were not detected in any of the tumors studied. conclusions. The results show that multiple ABC transporters were present in a cohort of sporadic patients with unilateral retinoblastoma who underwent primary enucleation. Studies are planned of the expression of ABC transporters in eyes treated by chemotherapy and/or radiation as a comparison with this group.